These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 28274402)

  • 1. Patient-reported quality of life during definitive and postprostatectomy image-guided radiation therapy for prostate cancer.
    Diao K; Lobos EA; Yirmibesoglu E; Basak R; Hendrix LH; Barbosa B; Miller SM; Pearlstein KA; Goldin GH; Wang AZ; Chen RC
    Pract Radiat Oncol; 2017; 7(2):e117-e124. PubMed ID: 28274402
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported quality of life during radiation treatment for localized prostate cancer: results from a prospective phase II trial.
    Chen RC; Zhang Y; Chen MH; McMahon E; Loffredo M; McPherson CP; Nguyen AU; Nguyen PL; D'Amico AV
    BJU Int; 2012 Dec; 110(11):1690-5. PubMed ID: 22502770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Image Guided Hypofractionated Postprostatectomy Intensity Modulated Radiation Therapy for Prostate Cancer.
    Lewis SL; Patel P; Song H; Freedland SJ; Bynum S; Oh D; Palta M; Yoo D; Oleson J; Salama JK
    Int J Radiat Oncol Biol Phys; 2016 Mar; 94(3):605-11. PubMed ID: 26867889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 2 trial of guideline-based postoperative image guided intensity modulated radiation therapy for prostate cancer: Toxicity, biochemical, and patient-reported health-related quality-of-life outcomes.
    Berlin A; Cho E; Kong V; Howell KJ; Lao B; Craig T; Bayley A; Chung P; Gospodarowicz M; Warde P; Catton C; Bristow RG; Ménard C
    Pract Radiat Oncol; 2015; 5(5):e473-e482. PubMed ID: 25899220
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Acute toxicity in definitive versus postprostatectomy image-guided radiotherapy for prostate cancer.
    Cheng JC; Schultheiss TE; Nguyen KH; Wong JY
    Int J Radiat Oncol Biol Phys; 2008 Jun; 71(2):351-7. PubMed ID: 18164841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective assessment of urinary, gastrointestinal and sexual symptoms before, during and after image-guided volumetric modulated arc therapy for prostate cancer.
    Sveistrup J; Widmark A; Fransson P; Iversen P; Munck Af Rosenschöld P; Engelholm SA; Petersen PM
    Scand J Urol; 2015 Feb; 49(1):58-69. PubMed ID: 24793783
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessment of late urinary, bowel and sexual function after dose escalation from 70 to 76 Gy using image-guided radiotherapy in curative treatment of prostate cancer.
    Haugnes HS; Melby B; Larsen KM; Langdal I; Rasi M; Bremnes RM
    Scand J Urol Nephrol; 2012 Apr; 46(2):124-32. PubMed ID: 22352316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported Outcomes and Late Toxicity After Postprostatectomy Intensity-modulated Radiation Therapy.
    Akthar AS; Liao C; Eggener SE; Liauw SL
    Eur Urol; 2019 Nov; 76(5):686-692. PubMed ID: 31113644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improved clinical outcomes with high-dose image guided radiotherapy compared with non-IGRT for the treatment of clinically localized prostate cancer.
    Zelefsky MJ; Kollmeier M; Cox B; Fidaleo A; Sperling D; Pei X; Carver B; Coleman J; Lovelock M; Hunt M
    Int J Radiat Oncol Biol Phys; 2012 Sep; 84(1):125-9. PubMed ID: 22330997
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing bowel and urinary domains of patient-reported quality of life at the end of and 3 months post radiotherapy between intensity-modulated radiotherapy and proton beam therapy for clinically localized prostate cancer.
    Bai M; Gergelis KR; Sir M; Whitaker TJ; Routman DM; Stish BJ; Davis BJ; Pisansky TM; Choo R
    Cancer Med; 2020 Nov; 9(21):7925-7934. PubMed ID: 32931662
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Image guided hypofractionated radiotherapy and quality of life for localized prostate cancer: prospective longitudinal study in 337 patients.
    Jereczek-Fossa BA; Santoro L; Zerini D; Fodor C; Vischioni B; Dispinzieri M; Bossi-Zanetti I; Gherardi F; Bonora M; Caputo M; Vavassori A; Cambria R; Garibaldi C; Cattani F; Matei DV; Musi G; De Cobelli O; Orecchia R
    J Urol; 2013 Jun; 189(6):2099-103. PubMed ID: 23313200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fitting NTCP models to bladder doses and acute urinary symptoms during post-prostatectomy radiotherapy.
    Mavroidis P; Pearlstein KA; Dooley J; Sun J; Saripalli S; Das SK; Wang AZ; Chen RC
    Radiat Oncol; 2018 Feb; 13(1):17. PubMed ID: 29394931
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A prospective analysis of health-related quality of life in intermediate and high-risk prostate cancer patients managed with intensity modulated radiation therapy, with vs. without hormonal therapy.
    Caumont F; Conti G; Hurwitz LM; Kuo C; Levie KE; Badiozamani K; Frankel JK; Flores JP; Brand TC; Chaurasia A; Rosner IL; Stroup SP; Musser JE; Cullen J; Porter CR
    Urol Oncol; 2020 Oct; 38(10):794.e1-794.e9. PubMed ID: 32139288
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer.
    Zelefsky MJ; Poon BY; Eastham J; Vickers A; Pei X; Scardino PT
    Radiother Oncol; 2016 Jan; 118(1):85-91. PubMed ID: 26780999
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute toxicity after image-guided intensity modulated radiation therapy compared to 3D conformal radiation therapy in prostate cancer patients.
    Wortel RC; Incrocci L; Pos FJ; Lebesque JV; Witte MG; van der Heide UA; van Herk M; Heemsbergen WD
    Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):737-44. PubMed ID: 25752386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between pelvic organ-at-risk dose and clinical target volume in postprostatectomy patients receiving intensity-modulated radiotherapy.
    Stanic S; Mathai M; Cui J; Purdy JA; Valicenti RK
    Int J Radiat Oncol Biol Phys; 2012 Apr; 82(5):1897-902. PubMed ID: 21536391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative toxicity and dosimetric profile of whole-pelvis versus prostate bed-only intensity-modulated radiation therapy after prostatectomy.
    Deville C; Vapiwala N; Hwang WT; Lin H; Ad VB; Tochner Z; Both S
    Int J Radiat Oncol Biol Phys; 2012 Mar; 82(4):1389-96. PubMed ID: 21664069
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-related quality of life results in pathologic stage C prostate cancer from a Southwest Oncology Group trial comparing radical prostatectomy alone with radical prostatectomy plus radiation therapy.
    Moinpour CM; Hayden KA; Unger JM; Thompson IM; Redman MW; Canby-Hagino ED; Higgins BA; Sullivan JW; Lemmon D; Breslin S; Crawford ED; Southwest Oncology Group
    J Clin Oncol; 2008 Jan; 26(1):112-20. PubMed ID: 18165645
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life after hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer.
    Quon H; Cheung PC; Loblaw DA; Morton G; Pang G; Szumacher E; Danjoux C; Choo R; Kiss A; Mamedov A; Deabreu A
    Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):617-23. PubMed ID: 22079736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated Dose Escalated 3D Conformal Radiotherapy for Prostate Cancer: Outcomes from a Mono-Institutional Phase II Study.
    Tramacere F; Arcangeli S; Pignatelli A; Castagna R; Portaluri M
    Anticancer Res; 2015 May; 35(5):3049-54. PubMed ID: 25964594
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.